[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335625-105":59,"doc-detail-335625-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pd-l1-from-cancer-immunotherapy-to-therapeutic-implications-in-multiple-disorders","PD-L1: From Cancer Immunotherapy to Therapeutic Implications in Multiple Disorders","","PD-L1/PD-1 signaling serves as a benchmark for cancer immunotherapy, supported by FDA-approved PD-1 and PD-L1 targeting antibodies used across multiple cancer types. Beyond its classical role as an immune checkpoint, PD-L1 contributes to tumor progression, including effects on cancer proliferation, transcriptional control, and systemic immune suppression. This review examines PD-L1 functions in additional diseases, evaluates PD-L1-centered therapeutic strategies, and discusses clinical relevance. It summarizes canonical and non-canonical pathways, including nuclear and secreted PD-L1 forms, and considers PD-L1 diagnostic potential and immunotherapy drug repositioning.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pd-l1-from-cancer-immunotherapy-to-therapeutic-implications-in-multiple-disorders/335625/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pd-l1-from-cancer-immunotherapy-to-therapeutic-implications-in-multiple-disorders/335625.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the canonical role of PD-L1 in the PD-1/PD-L1 signaling pathway?","Question",{"text":112,"@type":113},"PD-L1 binds PD-1 on activated T cells and recruits SHP-1 and SHP-2, which dephosphorylate downstream signaling factors from the TCR. This inhibitory feedback contributes to T cell exhaustion and prevents excessive T cell activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PD-L1 contribute to disease beyond its function as an immune checkpoint protein?",{"text":117,"@type":113},"The review describes PD-L1 involvement in cancer progression beyond checkpoint biology, including effects on cancer cell proliferation and transcriptional regulation. It also highlights systemic immune suppression via secreted PD-L1 forms and potential roles in other disease development and pathogenesis.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic directions does the review discuss for PD-L1-related diseases?",{"text":121,"@type":113},"It summarizes PD-L1-focused therapeutic approaches for cancers and non-cancer diseases and evaluates their clinical relevance. The review also considers repurposing existing immune checkpoint blockers developed for cancer using drug repositioning strategies, and discusses PD-L1 as a diagnostic marker.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335625,1790013863,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Review  \nPD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders  \nDaeun Lee, 1,4 Minjeong Cho,3,4 Eunseo Kim, 1,4 Youngbin Seo, 1 and Jong-Ho Cha 1,2  \n1Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences and Engineering Graduate School, Inha University, Incheon 22212, Republic of Korea; 2Biohybrid Systems Research Center, Inha University, Incheon 22212, Republic of Korea; 3Department of Biological Sciences, Inha University, Incheon 22212, Republic of Korea  \nThe PD-L1/PD-1 signaling pathway is the gold standard for cancer immunotherapy. Therapeutic antibodies targeting PD-1, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and PD-L1, including atezolizumab (Tecentriq), durvalumab (Imﬁnzi), and avelumab (Bavencio) have received Food and Drug Administration approval and are currently being used to treat various cancers. Traditionally, PD-L1 is known as an immune checkpoint protein that binds to the PD-1 receptor on its surface to inhibit the activity ofT cells, which are the primary effector cells in antitumor immunity. However, it also plays a role in cancer progression, which goes beyond traditional understanding. Here, we highlight the multifaceted mechanisms of action of PD-L1 in cancer cell proliferation, transcriptional regulation, and systemic immune suppression. Moreover, we consider the potential role of PD-L1 in the development and pathogenesis of diseases other than cancer, explore PD-L1-focused therapeutic approaches for these diseases, and assess their clinical relevance. Through this review, we hope to provide deeper insights into the PD-L1/PD-1 signaling pathway and present a broad perspective on potential therapeutic approaches for cancer and other diseases.  \nINTRODUCTION  \nProgrammed death-ligand 1 (PD-L1) is a crucial inhibitory immune checkpoint protein that regulates the functional balance of T cells, which is essential for maintaining homeostasis by eliminating pathogens as well as damaged and transformed cells.1 Mechanistically, PDL1 binds to the programmed cell death-1 (PD-1) receptor, providing negative feedback to activated T cells, causing exhaustion and preventing excessive T cell activation.2,3 Abnormally high PD-L1 expression can interfere with the proper functioning ofT cells, hindering the elimination of abnormal cells.4 Conversely, insufﬁcient PD-L1 expression can lead to an autoimmune response due to T cell hyperactivation.5 Dysfunctional cell accumulation and/or impaired autoreactivity, which are closely associated with disease progression, highlight how abnormal PD-L1/PD-1 signaling contributes to various diseases.  \nParticularly, cancer cells exploit PD-L1 to evade T cell surveillance, and many cancers exhibit elevated levels of this protein, thus neutralizing highly competent cytotoxic T lymphocytes (CTLs) in tumors  \nwith PD-L1 overexpression.6,7 Consequently, PD-L1 and PD-1 have become the gold standards in cancer immunotherapy, with researchers actively developing various immune checkpoint blockers (ICBs) that target these signaling pathways.7  \nRecent studies have revealed new PD-L1 subtypes and non-canonical PD-L1/PD-1 signaling pathways. This review provides a detailed summary of the research on intrinsic PD-1 signaling triggered by its expression in cancer cells, PD-L1 detected in the nucleus where it regulates the expression of genes associated with malignancy atthe transcriptional level, and secreted forms of PD-L1 that systemically suppress T cell immunity. Building on these insights, we explored the potential association of the PD-L1/PD-1 signaling pathway with various diseases, including cancer. Furthermore, we evaluated the potential of PD-L1 as a diagnostic marker for various diseases and discussed the possibility of repurposing ICBs initially developed for cancer treatment to treat other diseases using drug repositioning strategies.  \nNON-CANONICAL PATHWAY OF PD-L1/PD-1  \nSIGNALING  \nUpon activation, T cell","cbCaivHLkEp0mhYg","https://ap.wps.com/l/cbCaivHLkEp0mhYg","pdf",6251046,21,"English","# Introduction\n## Canonical PD-L1/PD-1 inhibitory checkpoint control\n## PD-L1 involvement in cancer immune evasion and disease progression\n# Non-Canonical Pathway of PD-L1/PD-1 Signaling\n## SHP-1/SHP-2 recruitment and T cell exhaustion in canonical signaling\n## Non-canonical roles: proliferation, nuclear transcriptional influence, and secreted immunosuppression\n# Therapeutic Implications and Clinical Relevance\n## PD-L1 as a diagnostic marker\n## Drug repositioning for non-cancer diseases","[{\"question\":\"What is the canonical role of PD-L1 in the PD-1/PD-L1 signaling pathway?\",\"answer\":\"PD-L1 binds PD-1 on activated T cells and recruits SHP-1 and SHP-2, which dephosphorylate downstream signaling factors from the TCR. This inhibitory feedback contributes to T cell exhaustion and prevents excessive T cell activation.\"},{\"question\":\"How does PD-L1 contribute to disease beyond its function as an immune checkpoint protein?\",\"answer\":\"The review describes PD-L1 involvement in cancer progression beyond checkpoint biology, including effects on cancer cell proliferation and transcriptional regulation. It also highlights systemic immune suppression via secreted PD-L1 forms and potential roles in other disease development and pathogenesis.\"},{\"question\":\"Which therapeutic directions does the review discuss for PD-L1-related diseases?\",\"answer\":\"It summarizes PD-L1-focused therapeutic approaches for cancers and non-cancer diseases and evaluates their clinical relevance. The review also considers repurposing existing immune checkpoint blockers developed for cancer using drug repositioning strategies, and discusses PD-L1 as a diagnostic marker.\"}]","PD-L1: From Cancer Immunotherapy to Therapeutic Implications in Multiple Disorders | PDF",1790011698,53]